Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

ARVINAS, INC. (ARVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 4 Peck Ronald (Chief Medical Officer) has filed a Form 4 on ARVINAS, INC.
Txns: Sold 1,324 shares @ $24.3871, valued at $32.3k
Exercised 4,010 restricted stock units @ $0
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant , including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer –"
06/08/2023 8-K Investor presentation
Docs: "EXHIBIT 99.1 Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line",
"June 8, 2023 ARV-766: Phase 1 and"
05/05/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Quarterly results
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/03/2023 4 Taylor Ian (Chief Scientific Officer) has filed a Form 4 on ARVINAS, INC.
Txns: Sold 1,051 shares @ $29.53, valued at $31k
Exercised 2,685 restricted stock units @ $0
03/03/2023 4 Houston John G (President and CEO) has filed a Form 4 on ARVINAS, INC.
Txns: Sold 5,878 shares @ $29.53, valued at $173.6k
Exercised 17,510 restricted stock units @ $0
03/03/2023 4 Cassidy Sean A (CFO) has filed a Form 4 on ARVINAS, INC.
Txns: Sold 1,745 shares @ $29.53, valued at $51.5k
Exercised 4,791 restricted stock units @ $0
02/24/2023 4 Cassidy Sean A (CFO) has filed a Form 4 on ARVINAS, INC.
Txns: Granted 19,125 shares @ $0
Granted 57,450 options to buy @ $34.37, valued at $2M
02/24/2023 4 Peck Ronald (Chief Medical Officer) has filed a Form 4 on ARVINAS, INC.
Txns: Granted 19,125 shares @ $0
Granted 57,450 options to buy @ $34.37, valued at $2M
02/24/2023 4 Houston John G (President and CEO) has filed a Form 4 on ARVINAS, INC.
Txns: Granted 61,975 shares @ $0
Granted 186,250 options to buy @ $34.37, valued at $6.4M
02/24/2023 4 Taylor Ian (Chief Scientific Officer) has filed a Form 4 on ARVINAS, INC.
Txns: Granted 19,125 shares @ $0
Granted 57,450 options to buy @ $34.37, valued at $2M
02/24/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer –"
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 9.3% stake in Arvinas, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 4.4% stake in ARVINAS INC
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.4% stake in Arvinas Inc.
02/09/2023 SC 13G/A FMR LLC reports a 10.6% stake in ARVINAS INC
02/07/2023 SC 13G/A BlackRock Inc. reports a 8.2% stake in Arvinas, Inc.
01/09/2023 8-K Investor presentation
Docs: "J.P. Morgan Healthcare Conference January 11, 2023"
12/23/2022 3 Loomis David K (Chief Accounting Officer) has filed a Form 3 on ARVINAS, INC.
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
12/16/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy